UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 9, 2013
KYTHERA BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-35663 |
|
03-0552903 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
27200 West Agoura Road,
Calabasas, California 91301
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (818) 587-4500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
Bayer has notified KYTHERA Biopharmaceuticals, Inc. that they now expect to file their ATX-101 Marketing Authorization Application in Europe in 2014.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: |
September 9, 2013 |
|
KYTHERA BIOPHARMACEUTICALS, INC. | |
|
|
| |||
|
|
By: |
/s/ Keith R. Leonard, Jr. | ||
|
|
|
Keith R. Leonard, Jr. | ||
|
|
|
| ||
|
|
|
President and Chief Executive Officer | ||